|Mr. Steven Saviuk||Chairman, Pres & CEO||392.5k||N/A||1959|
|Ms. Helen Saviuk||CFO & Director||200.46k||N/A||N/A|
|Mr. Ronald S. Perry CA, CPA||Sec. & Independent Director||N/A||N/A||1956|
|Mr. Marc Leger||Exec. VP of Commercial Operations - Valeo Pharma Inc||180.32k||N/A||N/A|
|Nathalie Therrien||Vice-Pres of QA & Regulatory Affairs - Valeo Pharma Inc.||170.08k||N/A||N/A|
Manitex Capital Inc., through its subsidiary, Valeo Pharma Inc., acquires and markets specialty pharmaceutical products, and distributes third-party pharmaceutical products primarily in Canada. It operates through two segments, Investments and Pharmaceutical. The company sells its products through wholesalers and retail pharmacy chains, as well as through hospitals and other groups. It also invests in marketable securities, as well as provides consulting services for private companies. Manitex Capital Inc. is headquartered in Kirkland, Canada.
Manitex Capital Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.